The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis
Not yet recruiting · NCT06833307 · Registry updated 2025-02-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis | Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | Not yet recruiting | Phase 3 | 2025-02-18 | NCT06833307 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 74 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Capital Medical University Affiliated Children's Hospital | Beijing | China | 1 |
| Shanghai Huashan Hospital | Shanghai | China | 1 |